Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Hanmi Science divulges new EZH inhibitors

March 11, 2022

Immuneering advances dual-MEK inhibitors

March 10, 2022

FDA grants orphan drug designation to BRD9 degrader CFT-8634 for soft tissue sarcoma

March 10, 2022

SKLB-0322 shows potent antitumor activity in models of ovarian cancer

March 10, 2022

IRAK4 as immunotherapeutic target in pancreatic ductal adenocarcinoma

March 10, 2022

Bolt Biotherapeutics presents new antibody-drug conjugates

March 10, 2022

Prelude Therapeutics identifies CDK9 inhibitors

March 10, 2022

Abbisko Therapeutics divulges new FGFR inhibitors

March 10, 2022

Aligos Therapeutics patents PRMT5 inhibitors

March 10, 2022

Targeting iASPP-TMCO1 axis may represent a promising therapeutic target in cancer

March 9, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...